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Abstract
This article provides a synopsis of the new dynamics of the global biopharma industry. The
emergence of global generics companies with capabilities approximating those of 'big pharma' has
accelerated the blurring of boundaries between the innovator and generics sectors. Biotechnology-
based products form a large and growing segment of prescription drug markets and regulatory
pathways for biogenerics are imminent. Indian biopharma multinationals with large-scale efficient
manufacturing plants and growing R&D capabilities are now major suppliers of Active
Pharmaceutical Ingredients (APIs) and generic drugs across both developed and developing
countries. In response to generic competition, innovator companies employ a range of life cycle
management techniques, including the launch of 'authorised generics'. The generics segment in
Australia will see high growth rates in coming years but the prospect for local manufacturing is
bleak. The availability of cheap generics in international markets has put pressure on Pharmaceutical
Benefits Scheme (PBS) pricing arrangements, and a new policy direction was announced in
November 2006. Lower generics prices will have a negative impact on some incumbent suppliers
but industrial renewal policies for the medicines industry in Australia are better focused on higher
value R&D activities and niche manufacturing of sophisticated products.
Background
The term biopharma captures a broadening of discussion
about pharmaceutical policy and the growing significance
of biotechnology. Indeed, the commercialisation of the
discoveries of the biological sciences, oriented towards an
understanding of living cells at the molecular level, is
widely seen as potentially sustaining another long wave of
economic growth, 'making reality of the prediction that
this will be the century of biotechnology' [[1], p. 5, see
also [2]]. The long-established 'big pharma' companies
headquartered in the US and Europe – roughly those
listed in Pharmaceutical Executive's annual company rank-
ing – are in the midst of 'an extremely painful transition'
driven by a confluence of scientific-technological, eco-
nomic and regulatory-political factors [3,10]. Generic
competition has led many of these firms into take-overs
and mergers, and a flurry of alliances and other agree-
ments with major generic players. Pricing pressures, safety
recalls and marketing scandals also challenge an industry
which has, for decades, been enormously profitable [4,5].
The industry's research and development (R&D) produc-
tivity crisis is a crucial factor driving new business strate-
gies. In recent years, established R&D systems have seen
only a trickle of new drugs emerging. The 20 new molec-
ular entities approved by the Food and Drug Administra-
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tion (FDA) in 2005 were fewer than half of the number
approved in 1996 [6]. This would not be such a problem
if many of the new products were of major therapeutic
and commercial significance. But most newly launched
drugs provide marginal health benefits only, and com-
mercial returns are then constrained by the cost-effective-
ness hurdles imposed by public and private purchasing
organisations. A French study reports that '68 percent of
the 3,096 new products approved in France between 1981
and 2004 brought "nothing new" to existing treatments'
[7].
Some new drugs, of course, do bring significant therapeu-
tic benefits, and biotechnology has opened up promising
new avenues for drug discovery. Sales of biologicals (bio-
technology-based drugs) in 2005 grew about three times
faster than the small molecule market, reaching about
US$52 billion. Biologicals are reported to account for
27% of new medicines under development, but the pros-
pect of a wave of new break-through medicines, compara-
ble to the synthetic drugs of post-1945 decades, has not
yet been realised [8-11]. 'Big pharma' companies have
responded to cost and profit pressures with consolidation
into ever larger entities, combined with outsourcing, and
other types of exchange, with external organisations [12-
14]. The result is a global pattern of production and inno-
vation networks encompassing linkages between 'big
pharma' and smaller R&D intensive firms and a variety of
new commercial players, such as clinical research organi-
sations, some of which (for example Quintiles) are close
to billion dollar companies in their own right [15]. Agree-
ments with generics firms, to thwart the full impact of
competition in off-patent markets, are also on the rise.
The US remains the central node of these networks. Public
funding for medical research is of greater magnitude in
the US than anywhere else; the world's largest medical
research funding organisation, the National Institutes of
Health, has a budget of around US$28 billion. Half of the
top 10 pharma companies are headquartered in Europe –
GlaxoSmithKline, Sanofi-Aventis, Novartis, AstraZeneca
and Roche – but a significant proportion of their R&D is
undertaken in the US. The significance of India, China,
South Korea and other Asian countries is growing [10]. As
detailed further below, Indian firms have achieved a posi-
tion as significant players in global biopharma markets. In
particular, low costs coupled with high quality personnel
make Indian firms competitive suppliers of manufactur-
ing and R&D services, and other outsourced activities. In
some areas, notably in the production of Active Pharma-
ceutical Ingredients (APIs), there are now no technology
gaps between Indian and Western firms [16,17]. The cred-
ibility of Indian drug firms has benefited from the reputa-
tion of Indian companies in the global market for
information technology-based Business Process Out-
sourcing (BPO) services [18,19]. China is considered to be
ahead of India in biology and to have made notable
advances in gene therapy and stem cell research, but the
top tier of the Indian drug companies such as Ranbaxy
and Dr Reddy's Laboratories (DRL), which also have
extensive biotechnology capabilities, have a stronger pres-
ence in global markets.
Present changes to Australian drug pricing arrangements
(see the editorial accompanying this article) are driven by
concerns that the Pharmaceutical Benefits Scheme (PBS)
provides for unnecessarily high prices for generic prod-
ucts. This contention is confirmed in the following analy-
sis, which explores the complexities of the global generics
sector and elucidates the context for Australian medicines
policy.
Generics and global industry dynamics
The modern generic pharmaceutical industry came into
existence through the 1984 US Drug Price Competition
and Patent Restoration (Hatch-Waxman) Act, which pro-
vided for facilitated market entry for generic versions of all
post-1962 approved products in exchange for an exten-
sion of the patent period for the original drug [20,21]. As
more generics became available, US health maintenance
organisations and pharmacy benefit management compa-
nies encouraged or mandated measures such as generic
prescribing, brand substitution by pharmacists, and reim-
bursement on the basis of cheapest brand. In 2005, more
than 60% of prescriptions in the US were filled with a
generic. Their established role in the US effectively
debunks the disparagement of generics that is still occa-
sionally forthcoming from brand industry sources such as
the Pharmaceutical Research and Manufacturers of Amer-
ica (PhRMA) [22]. Other countries with highly developed
generics markets include the UK, Germany, the Nether-
lands, Canada, and the Nordic countries, and generics
markets are expanding rapidly, from a lower base, in
France, Spain, Italy, Russia, Latin America, Australia, and
elsewhere [23].
As patents expire on many big-selling products, 'about
$100 billion worth of brand-name drugs will lose patent
exclusivity [in the US] during the next five years, including
products going off patent in 2006 that will generate about
$21 billion in combined sales' [24]. Recent examples
include Pfizer's antidepressant Zoloft (sertraline) and
Merck's anti cholesterol drug Zocor (simvastatin), which
both lost US patent protection in June 2006. The world's
largest generics company, Teva, headquartered in Israel,
and the Indian firm Ranbaxy (tenth in global generics
rankings) obtained 180 days US exclusivity for generic
simvastatin of various strengths. The availability of
generic simvastatin has flow-on implications across the
anti-cholesterol market, which in 2004 had a global valueAustralia and New Zealand Health Policy 2007, 4:10 http://www.anzhealthpolicy.com/content/4/1/10
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of about US$25 billion [25]. In Australia, generic brands
of simvastatin were first listed on the PBS on 1 August
2005. It was envisaged initially that the reference pricing
system would trigger a price reduction for all brands in the
statin group of drugs, but the PBAC accepted a submission
from Pfizer for Lipitor to be excluded from the price cut on
the grounds of being ' more effective than simvastatin in
lowering cholesterol' [26].
Plavix, one of the world's highest selling drugs at about
US$4 billion in 2005, marketed in the US by Bristol-
Myers Squibb (BMS) for Sanofi-Aventis, is another recent
example of a major product going off patent. In August
2006, the Canadian company Apotex after complex legal
wranglings launched a generic version of Plavix. Within
days, close to 80% of new prescriptions in the US were
filled with the Apotex generic, and BMS and Sanofi-
Aventis lost around US10 billion in market value [27,28].
The next big generics development is the introduction of
regulatory pathways for biogenerics. These are generic ver-
sions of biotechnology-based drugs (biopharmaceuticals
or biologics) such as insulin and human growth hor-
mone, that is, large-protein molecules derived from living
cells. Biogenerics involve a substantial innovative input,
and are therefore not strictly generic medicines in the tra-
ditional regulatory sense, and are sometimes referred to as
biosimilars or follow-on protein products. But they are
sufficiently similar to a product already approved to make
substitution possible. The cost of the original biologics is
typically well in excess of US$10,000 per patient per year,
and this market is growing much faster than sales of tradi-
tional drugs. In 2005 the value of biopharmaceuticals in
the US was around US$30 billion [29]. Australia's Thera-
peutic Goods Administration (TGA) was the first regula-
tory agency, in 2004, to approve a biogeneric, namely
Omnitrope for treatment of growth disorders, supplied by
Sandoz. Omnitrope has since been approved also in the
European Union and the US.
The complexity of biogenerics manufacturing, and regula-
tory uncertainties, have so far protected originator prod-
ucts from competition even when patents have expired.
Regulatory processes for biogenerics are not yet stream-
lined but the case of Omnitrope is a sign of things to come
[30]. Several companies including Indian firms stand
ready to launch biogenerics. Technical barriers to entry
make this market, if anything, more appealing to generics
players with requisite technological capabilities. Major
originator products are expected to give rise to only one or
two biogenerics, likely to be priced 25 to 40% below the
original. This translates into profit margins much higher
than in generic small-molecule markets where price falls
tend to be much steeper [31,32].
To counteract the threat of generic competition, 'big
pharma' applies a range of sophisticated 'life cycle man-
agement' techniques, notably the 'evergreening' of patent
protection through the embedding of brands in intricate
clusters of patents which make challenges complex and
expensive [15,33]. Other techniques include the packag-
ing of two existing drugs, about to go off patent, into a sin-
gle new patented drug. For example, Pfizer's Caduet,
containing both Lipitor and Norvasc, is expected to retain
patent protection in the US until 2018, long after compe-
tition has eroded the value of its basic chemical ingredi-
ents [[5], p. 72]. The patenting of a marginally modified
version of the original chemical substance, coupled with
massive marketing campaigns to switch patients to the
newly patented product, has also proven commercially
effective. The industry standard in this type of strategy was
set by AstraZeneca which successfully launched Nexium
when Losec/Prolosec was about to lose patent protection.
Nexium 'has been found to be pretty much identical to
Prilosec and about ten times more expensive' [[5], p. 76].
Other ways of managing the 'life cycle' of drugs include
new delivery technologies (such as once-a-day formula-
tions), new indications which may bring additional peri-
ods of exclusivity, switch to over-the-counter (OCT)
status, and so-called 'exclusion payments' made 'when a
branded company shares a portion of its future profits
with a potential generic entrant in exchange for the
generic's agreement not to market its product' [[23,34], p.
6].
Blurring of originator and generic categories
This complex environment leaves little scope for 'tradi-
tional' generics companies competing solely on price.
Indeed, mergers and acquisitions have brought forth a
small number of multinational generics majors, with
technological, legal, and marketing capabilities approxi-
mating those of 'big pharma'. Firms in this group include
Teva, Mylan Laboratories, Actavis, Barr (which in 2006
acquired Pliva, the largest drug company in Eastern and
Central Europe), Watson (recently merged with Andrx,
another generics major), and the Indian companies Ran-
baxy and DRL. These are companies dealing also in pro-
prietary products such a new drug delivery technologies,
and in some cases they engage in the development of new
innovative drugs [23]. Merck KGaA, the parent company
of Alphapharm in Australia, is a long-standing member of
this group, but has declared a full-scale shift into the inno-
vator category (following the acquisition of Serono, a
large biotech company) and its generics division has been
off-loaded the US-based generics major Mylan Laborato-
ries. The blurring between the brand-name (originator,
innovative) and generics sectors is demonstrated most
starkly by Sandoz, which ranks globally as the second larg-
est of the generics suppliers (after Teva). Sandoz was
established by Novartis (the world's fourth largest pharmaAustralia and New Zealand Health Policy 2007, 4:10 http://www.anzhealthpolicy.com/content/4/1/10
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company) in 2002 from a collection of previously existing
subsidiaries. Similarly, Sanofi-Aventis has created Win-
throp Pharmaceuticals 'to position the Group ... as a
major actor on the generics market' [35]. It makes good
sense for Novartis and Sanofi-Aventis to supplement the
core business of patented products with a strong presence
also in the generics market. In the US and elsewhere, a
capacity to supply an extensive range of products, includ-
ing off-patent drugs, can be a competitive advantage.
The phenomenon of authorised generics, also known as
pseudo-generics or fighting-brands, represents an intrigu-
ing form of life cycle management. This refers to brand-
name products given a generic label; the 'brand-name
manufacturer either sell [s] the authorized generic itself
through a subsidiary or licens [es] a generic firm to sell the
authorized generic' [[34], p. 27]. This practice is the sub-
ject of heated debate in the US and is viewed by the Fed-
eral Trade Commission as potentially illegal anti-
competitive conduct. Pseudo-generics can be harmful to
consumers 'because an expectation of competition from
authorized generics will significantly decrease the incen-
tives of generic manufacturers to pursue entry prior to pat-
ent expiration [through patent challenges], especially for
"non-blockbuster" drugs' [[34], p. 28]. Authorised gener-
ics would seem to have become common also in Australia
but a detailed analysis of their impact on local market
dynamics is yet to be undertaken [but see [36]].
Patent expiries and the growth of the generics sector is
only one of the factors which explain the changing
dynamics of the global biopharma industry. A major
trend is the expansion of outsourcing by the major com-
panies across a range of functional areas, including man-
ufacturing, and R&D and clinical trials. It is striking that
Asian and in particular Indian firms are now highly com-
petitive providers of outsourcing services including supply
of APIs [3,17,22,23,37,38].
India's biopharma multinationals
India's large biopharma industry is one of the country's
economic success stories. Some Indian drug companies
were established well before the Second World War. The
modern drug industry emerged however from the 1970s,
behind high tariffs and through other protectionist meas-
ures [39,40]. In 1972, patents for pharmaceutical (and
food and agrochemical) products were disallowed and
only one production process could be patented (for a
maximum seven years). Indian firms proved capable,
often through collaborations with public sector research
organisations, of developing alternative processes for the
production of most APIs and generics, drawing on a
strong chemical engineering tradition.
The industry has now reached a scale and scientific-tech-
nological sophistication which make Indian firms impor-
tant global players. In volume terms, India's drug industry
is the fourth largest in the world; around 20% of the glo-
bal production of APIs and formulations is estimated to
derive from Indian manufacturing plants [41]. The
domestic market is, along with Japan's, unique in not
being dominated by 'big pharma'. In 2005, Indian firms
were reported to meet 'around 70% of the domestic
demand for bulk drugs, drug intermediates, pharmaceuti-
cal formulations, chemicals, tablets, capsules, orals and
injectables' [[42], p. 10]. The competitiveness of top-tier
firms draws on an abundant supply of engineering and
science graduates and 'the world's second largest annual
pool of English-speaking medical professionals after the
US' [[43], p. 57]. For lower pay than an equivalent profes-
sional in the US, 'a full-time chemist in India is better edu-
cated ... [and] the time spent on the job is longer' [[44], p.
198]. Indian drug have been exported to developing coun-
tries for several decades, and more recently exports to
North America and Europe have increased rapidly. With
marketing infrastructure, production plants and R&D
facilities in Europe and North America, and a long-stand-
ing presence in many developing countries, the top com-
panies are true multinationals. A recent wave of overseas
acquisitions, notably several medium-sized local generics
firms across Europe, consolidates their presence in inter-
national markets [45]. Ranbaxy, which launched its first
PBS products in 2006, claims to be 'no longer an Indian
company': ' [o]ur origins are in India, but we are truly a
global pharmaceutical company' [46].
The Trade Related Intellectual Property Rights (TRIPS)
agreement of 1995 has been a key driver of the outward
orientation of Indian drug firms. TRIPS, one of the three
pillars of the World Trade Organization (WTO), the oth-
ers being trade in goods and services, mandated the intro-
duction of globally harmonised intellectual property
rights (IPRs). India was given a ten year transition period,
and in 2005 took the final step in making its IPR regime
TRIPS compliant. The most essential aspect of the new
patent system is the disallowance of the 'reverse engineer-
ing' model which underpinned the drug industry's expan-
sion in the preceding three decades. The industry initially
had deep misgivings about TRIPS, which removed its
major competitive advantage, but the leading companies
have now adapted their business strategies to the new reg-
ulatory environment [39,40,47,48]. Apprehensions today
are expressed not so much by the industry but by health
activists and non-government organisations, and focus on
the implications of TRIPS for affordable drug access for
the poor in India, and in other developing countries
which have hitherto been able to import relatively cheap
generics from India. Most already marketed generic med-
icines will continue to be available under TRIPS, but itAustralia and New Zealand Health Policy 2007, 4:10 http://www.anzhealthpolicy.com/content/4/1/10
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prevents the production and exports of generic versions of
new patented drugs, for example any new break-through
HIV/AIDS medications, unless compulsory licensed, or
voluntarily licensed by the patent holder [49,50].
Until recently, Indian firms expended only 2–3% of reve-
nue on R&D, and drug discovery research was undertaken
in public sector research institutes only, but the last dec-
ade has seen a steady rise in private sector R&D, spurred
by the new IPR regime. In 2006 more than 175 companies
had established R&D centres recognised by the Depart-
ment of Scientific & Industrial Research. Around 15 com-
panies are reported to be engaged in discovery research,
spending around 10% of revenue on R&D [51]. Ranbaxy,
DRL, Nicholas Piramal, and several other firms, have mol-
ecules in advanced stages of clinical testing, and the indus-
try in total is reported to have about 60 compounds in
various phases of development though no company has
yet brought a drug to market [52]. The industry's total
annual R&D investment is estimated at around US$170
million, which is miniscule compared to that of 'big
pharma', though this expenditure 'buys' more R&D in
India than in North America or Europe due to lower
labour costs and perhaps harder efforts [53].
Rather than head-on competition, alliances with 'big
pharma' and the global generics companies form the pri-
mary growth strategy for the leading Indian companies.
The resources required to take a promising molecule
through testing and regulatory approval, and then the
costs of marketing in Western countries, are of such mag-
nitude that out-licensing to 'big pharma' is the predomi-
nant model [39]. As noted, the established global
companies now outsource to India a range of activities
including manufacturing and packaging, discovery
research, clinical trials, and data management. Global
biopharma outsourcing was valued in 2005 at around $60
billion, half of which encompassing R&D activities
including clinical trials [54]. Clinical Research Organisa-
tions (CROs) in India are rapidly expanding and were
reported in 2005 to be worth around $75 million [14].
India offers many advantages: a vast population of
patients with a diverse gene pool, easily recruited and with
little previous contact with modern medicine; availability
of qualified English-speaking doctors, pharmacists and
science graduates; a large number of hospitals and other
institutions of good quality; and now protection for intel-
lectual property. The cost of conducting clinical trials in
India is estimated at 'almost one-third of the costs of the
equivalent in the Western world' [44].
Large-scale, efficient manufacturing remains India's core
competitive advantage in the biopharma sector. Around
75 plants are approved by the US Food and Drug Admin-
istration (the largest number of approved units outside
the US) and many have Good Manufacturing Practice
(GMP) clearance from Australia's Therapeutic Goods
Administration (TGA) [14]. The marketing by Indian
firms of their own products in Western markets is still at
an early stage, though the chemical ingredients in many
products carrying 'big pharma' brand names, or the labels
of international or local Australian generics suppliers, are
produced in Indian or other Asian plants. 'Big pharma'
have always sourced APIs from European manufacturers
but Chinese and Indian firms, drawing on a lower cost
base, have emerged as major API suppliers. In 2005,
India's API industry was the world's third largest, after
China and Italy, growing at an annual rate of close to 20%
[16]. Indian producers supply sophisticated APIs includ-
ing still patented products to a greater extent than Chinse
firms, which dominate in the market for off-patent com-
modity bulk drugs [16,17]. API costs, typically represent-
ing 40–50% of the value of generic oral solids, are critical
to competitiveness in the generics industry [55,56].
India's biopharma innovation system lags behind the
developed countries and even the largest of India's drug
firms, Ranbaxy, is not ranked among the world's top 50
pharma companies [10]. But the entry of Indian firms into
developed country generics markets has reinforced com-
petition and price pressures; global 'pricing competition
[is] driven by a huge overcapacity ... because of all the
investments that have been made in India and are going
to be made in China' [57]. Indicative of the confidence of
Indian manufacturers is the claim by a Hyderabad-based
company that it has the capacity to supply the US generics
market, with a 30–40% margin, even after a 97% price
collapse following patent expiry (personal communica-
tion, April 2006). Clearly, changes in international gener-
ics market, particularly the rise of Indian suppliers,
provide a context for consideration of options for Austral-
ian PBS reform.
Conclusion: implications for Australia
There are implications for two of the core aims of Aus-
tralia's well respected national medicines policy flowing
from the preceding sketch of developments in interna-
tional markets. First, 'access to medicines', that is, the
future of the PBS and, second, a 'responsible and viable
industry in Australia', that is, the promotion of business
activity in the biopharma sector [58].
Plainly, the expiry of many drug patents, and the strength-
ening of the global generics sector, opens up opportuni-
ties for PBS measures to extend the use of cheaper
generics. This is a recognition which underpins the policy
initiatives announced in November 2006, discussed in the
adjoining editorial. It no longer makes sense to accept
large gaps between PBS generics prices, and the prices at
which many products can be sourced in internationalAustralia and New Zealand Health Policy 2007, 4:10 http://www.anzhealthpolicy.com/content/4/1/10
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markets. The Department of Health and Ageing has long
been aware of this discrepancy, highlighted in a March
2005 press release which compared prices for several off-
patent products in Australia, the UK and New Zealand. In
the case of fluoxetine 20 mg, the PBS price was reported to
be $33.03, the price in the UK $4.97 and in New Zealand
$1.45 [59]. It has also irked the government that a large
proportion of costs benefits from cheaper generics have
flowed to retail pharmacists rather than tax payers, an
anomaly addressed in the policy package about to be pre-
sented to parliament [60,61]. In 2006 the introduction of
a tendering system was reported to be under considera-
tion but this idea was abandoned in the face of opposition
from both suppliers and retail pharmacists [62].
Promotion of a local generics industry has figured as a
policy aim within the context of the Pharmaceuticals
Industry Action Agenda, pursued by the Department of
Industry, Tourism and Resources since 2001. But this
objective would seem to have been progressively down-
graded for good reasons. The blurring of boundaries
between the originator and generics sectors, internation-
ally and in Australia, as outlined in this paper, make the
notion of a distinct generics industry largely obsolete. The
Australian generics market will undoubtedly see high
growth rates in coming years: it is anticipated, even before
any new legislation, that the present level of 25% of pre-
scriptions filled with a generic 'will almost double in the
next five years as more than half of the top 100 selling pre-
scription medicines in Australia will be off patent and be
substituted by generic branded drugs'. By 2009, it is
expected that 'over 200 generic drugs will account for a
dispensed value of approximately $1.7 billion' [[63], p.
12]. This does not translate however into good prospects
for a generics manufacturing industry in Australia. The
final stage of manufacturing and packaging of generics is
essentially low-tech commodity production and, as in
other areas of low-tech manufacturing, Australian-based
plants are unlikely to be internationally competitive. The
scale of generics manufacturing at individual production
plants in India (and indeed China) is well beyond any-
thing that can be envisaged for Australia. Recent entrants
to the Australian generics market such as Genepharm
source all products from overseas and this is the way of the
future.
The policy measures announced in November 2006 will
hurt incumbent generics suppliers, but broader negative
economic effects will be marginal since Australia does not
have significant manufacturing of either off-patent APIs or
generic formulations. The structure of the Australian
generics industry is highly skewed in favour of two com-
panies; Alphapharm (now a subsidiary of Mylan Labora-
tories) and Sigma Pharmaceuticals control more than
80% of the market. The proliferation of authorised gener-
ics and shadowy discount practices weaken any case for
protection of incumbent suppliers against competition
from Indian and other new entrants. As noted, global
industry dynamics provide little scope for Australia to
become a significant drug manufacturing centre, with
many generics heading towards commodity status. The
scale advantages of manufacturers in India and elsewhere
are such that Australian policy makers should instead
focus on R&D-intensive biopharma sector activities, par-
ticularly in the biotech area where Australia retains a com-
petitive advantage [64].
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